First-in-human Study of S-588210 (S-488210+S-488211)

Phase 1 Completed 10 enrolled Shionogi

NaSingle-groupOpen-labelTreatment

Summary

The primary objective is to evaluate the safety and tolerability of S-588210 (S-488210+S-488211) in patients with unresectable recurrent and/or metastatic solid tumors.

Timeline

Start: 2019-07-30
Primary completion: 2021-09-22
Completion: 2021-09-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	S-488210	Vaccine	1 mg	Subcutaneous
Subject	S-488211	Vaccine	1 mg	Subcutaneous

First-in-human Study of S-588210 (S-488210+S-488211)

Summary

Timeline

Drugs

Indications